# TRIB earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/TRIB) · [Earnings tab](https://www.lopjlb.com/stock/TRIB?tab=earnings)

Updated: 2026-09-03T06:33:35

Quarters analyzed: 8

## Cross-quarter narrative

Across the series of calls, Trinity Biotech’s narrative shifted from early‑stage uncertainty and regulatory bottlenecks in 2023 toward a more execution‑focused transformation by 2024. Initial quarters highlighted strong autoimmune and diabetes demand but flagged pending FDA clearances and Kenyan legal challenges that threatened revenue timing. By Q2 2023 the company secured FDA clearance for its hemoglobin analyzer, yet liquidity concerns and supply‑chain dependencies persisted. The acquisition of Waveform biosensor assets in Q3 2023 marked a strategic pivot to CGM technology, accompanied by a non‑binding Bayer partnership and a re‑engineered cost structure. In 2024 the firm emphasized rapid‑HIV test scaling, point‑of‑care growth, and continued CGM prototype development, while confronting Nasdaq compliance and execution risks around automation and offshore assembly. Margin dynamics improved through supply‑chain optimization, though the high‑margin HIV product initially diluted overall gross margin. Regulatory and legal risks remained constant, but liquidity worries receded as debt was reduced. Overall, the calls reflect a transition from regulatory‑driven uncertainty to operational scaling and product diversification, with persistent challenges in Kenya, margin mix, and CGM trial execution.

## Latest CallCard · Q3

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2024 Q3:** —
- **2024 Q2:** Trinity Biotech reports strong 50% QoQ growth in point‑of‑care revenue driven by TrinScreen HIV, advances its offshore manufacturing and supply‑chain transformation, and moves CGM prototypes toward user testing while reaffirming its $75 M revenue and $20 M EBITDASO guidance for Q2 2025.
- **2024 Q1:** Trinity Biotech reports 40% QoQ Point‑of‑Care growth from rapid HIV test ramp‑up, improved gross margins, on‑track $75M revenue/ $20M EBITDASO guidance, progressing CGM development, but faces Nasdaq compliance risk and execution challenges.
- **2023 Q4:** Trinity Biotech Q4 2023 call highlighted revenue decline, a $20M EBITDASO target by 2025, cost‑cutting initiatives, biosensor acquisition progress and growth focus on point‑of‑care and international markets.
- **2023 Q3:** Trinity acquires Waveform reusable CGM tech, partners with Bayer for China/India, secures Perceptive financing; Q3 rev $14.7M (-6.4%), gross margin 29.2% (35.5% ex-obsolescence), cash $6.3M.
- **2023 Q2:** Trinity Biotech posted flat Q2 revenue, highlighted strong 70% Asia diabetes consumables rebound, secured FDA clearance for its haemoglobin analyzer, but faces Kenya legal hurdles, cash‑flow concerns and ongoing cost‑cutting initiatives.
- **2023 Q1:** TRIB reported Q1 revenue of $14.8M, highlighted strong autoimmune and diabetes demand, pending FDA clearance and Kenya HIV launch amid legal delays, and outlined cost and debt‑reduction initiatives.
- **2022 Q4:** —

## Theme arcs

- **Liquidity/financial risk** (resolved): Early cash‑flow concerns in Q2 2023 eased after debt reduction and financing actions
- **Execution & transformation** (improving): Progress on automation, offshore assembly, and facility closures shows execution momentum
- **Demand diversification** (improving): Shift from autoimmune/diabetes to point‑of‑care HIV and emerging CGM markets
- **CGM development** (new): Introduced in Q3 2023 and advanced through prototypes and trial planning in 2024
- **Nasdaq compliance** (new): Raised as a risk in Q1 2024 with potential financing implications

## Fear persistence

- **Regulatory** [recurring]: FDA clearance and CGM approval risks appear in every quarter
- **Legal (Kenya)** [recurring]: Court challenges to HIV algorithm persist through 2024
- **Margin pressure** [recurring]: Mix shift and low‑margin HIV test affect gross margin
- **Liquidity** [resolved]: Cash concerns voiced in Q2 2023, later absent
- **Execution** [recurring]: Risks around insourcing, automation, and transformation noted throughout
- **Market adoption (CGM)** [recurring]: Uncertainty over CGM uptake and trial design continues
- **Nasdaq compliance** [new]: Raised as a risk in Q1 2024 only

## Guidance path

2022 Q4:vague → 2023 Q1:vague → 2023 Q2:maintained → 2023 Q3:vague → 2023 Q4:maintained → 2024 Q1:maintained → 2024 Q2:maintained → 2024 Q3:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/TRIB`